Autism is a chronic and lifelong pervasive developmental disorder for which there is yet no effective cure, and medical management remains a major challenge for clinicians. In spite of the possible similarities with conditions that have an established pharmacotherapy, and despite improvements in some associated "problematic behaviors" following the use of available medications, effective medical treatment for the core symptoms involving language and social cognition remains elusive. The purpose of the present article is to review current biologic knowledge about autism in an attempt to correlate clinical trials with known mechanisms of disease. In addition, the need for controlled studies and for the creation of homogeneous subgroups of patients based on clinical and genetic characteristics is emphasized. The application of molecular genetic investigations and pharmacogenetics in the diagnostic work-up of autistic patients can lead to more effective individualized medical care.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Press, 1994.
2.
RapinI: The autistic-spectrum disorders. N Engl J Med2002;347:302–303.
3.
EhlersS, GillbergC: The epidemiology of Asperger syndrome. A total population study. J Child Psychol Psychiatry1993;34:1327–1350.
4.
BertrandJ, MarsA, BoyleC, : Prevalence of autism in a United States popluation: The Brick Township, New Jersey, investigation. Pediatrics2001;108:1155–1161.
5.
KadesjoB, GillbergC, HagbergB: Brief report: Autism and Asperger syndrome in seven-year-old children: A total poplation study. J Autism Dev Disord1999;29:327–331.
6.
LotterV: Epidemiology of autistic conditions in young children, I. Prevalence. Soc Psychiatry1974;1:124–137.
7.
BairdG, CharmanT, Baron-CohenS: A screening instrument for autism at 18 months of age: A 6-year follow-up study. J Child Psychol Psychiatry2000;39:694–702.
8.
BrysonSE: Epidemiology of autism: Overview and issues outstanding, in CohenDJ, VolkmarFR (eds): Handbook of Autism and Pervasive Developmental Disorders, 2nd ed. New York, Wiley, 1997, 41–46.
9.
BaileyA, Le CouteurA, GottesmanI, : Autism as a strongly genetic disorder: Evidence from a British twin study. Psychol Med1995;25:63–77.
10.
RutterM, SilbergJ, O'ConnorT, SimonoffE: Genetics and child psychiatry: II Empirical research findings. J Child Psychol Psychiatry1999;40:19–55.
11.
KemperTL, BaumanM: Neuropathology of infantile autism. Neu J.-ropathol Exp Neurol1998;57:645–652.
12.
RitvoER, FreemanBJ, ScheibelAB, : Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC Autopsy Research Report. Am Psychiatry J.1986;143:862–866.
13.
CourchesneE: Brainstem, cerebellar and limbic neuroanatomi-cal abnormalities in autism.Curr Opin Neurobiol1997;7:269–278.
14.
SalmondCH, de HaanM, FristonKJ, : Investigating individual differences in brain abnormalities in autism.Philos Trans R Soc Lond B Biol Sci2003;358:405–413.
15.
TsatsanisKD, RourkeBP, KlinA, : Reduced thalamic volume in high-functioning individuals with autism.Biol Psychiatry2003;53:121–129.
16.
HerbertMR, HarrisGJ, AdrienKT, : Abnormal asymmetry in language association cortex in autism.Ann Neurol2002;52:588–596.
17.
RischN, SpikerD, LotspeichL, : A genomic screen of autism: Evidence for a multilocus etiology.Am Hum J. Genet1999;65:493–507.
18.
AuranenM, NieminenT, MajuriS, : Analysis of autism susceptibility gene loci on chromosomes lp, 4p, 6q, 7q, 13q, 15q, 16p, 17q, 19q and 22q in Finnish multiplex families.Mol Psychiatry2000;5:320–322.
19.
PhilippeA, MartinezM, Guilloud-BatailleM, : Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study.Hum Mol Genet1999;8:805–812.
20.
BarrettS, BeckJC, BernierR, : An autosomal genomic screen for autism. Collaborative linkage study of autism.Am J Med Genet1999;88:609–615.
LucarelliP, PalminielloS, SaccucciP, : Association study of autistic disorder and chromosome 16p.Am Hum J. Genet2003; 119A(2):242–246.
23.
CookEHJr, CourchesneRY, CoxNJ, : Linkage-disequilibrium mapping of autistic disorder, with 15qll-13 markers.Am Hum J. Genet1998;62:1077–1083.
24.
GurrieriF, BattagliaA, TorrisiL, : Pervasive developmental disorder and epilepsy due to maternally derived duplication of 15qll-ql3.Neurology1999;52:1694–1697.
SmalleySL, KustanovichV, MinassianSL, : Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16pl3, in a region implicated in autism. Am Hum J. Genet2002;71:959–963.
27.
International Molecular Genetic Study of Autism Consortium: A full genome screen for autism with evidence for linkage to a region on chromosome 7q. Hum Mol Genet1998;7:571–578.
28.
Ashley-KochA, WolpertCM, MenoldMM, : Genetic studies of autistic disorder and chromosome 7.Genomics1999;61:227–236.
29.
Veenstra-Vander WeeleJ, KimSJ, LordC, : Transmission disequilibrium studies of the serotonin 5-HT2A receptor gene (HTR2A) in autism. Am J Med Genet2002;114:277–283.
30.
ZhangH, LiuX, ZhangC, : Reelin gene alleles and susceptibility to autism spectrum disorders.Mol Psychiatry2002;7:1012–1017.
31.
KrebsMO, BetancurC, LeroyS, : Absence of association between a polymorphic GGC repeat in the 5’ untranslated region of the reelin gene and autism.Mol Psychiatry2002;7:801–804.
32.
PersicoAM, D'AgrumaL, MaioranoN, : Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder.Mol Psychiatry2001;6:150–159.
33.
PersicoAM, PascucciT, Puglisi-AllegraS, : Serotonin transporter gene promoter variants do not explain the hypersero-toninemia in autistic children.Mol Psychiatry2002;7:795–800.
34.
BottiniN, De LucaD, SaccucciP, : Autism: Evidence of association with adenosine deaminase genetic polymorphism.Neurogenetics2001;3:111–113.
35.
CuratoloP, VerdecchiaM, BombardieriR: Tuberous sclerosis complex: A review of neurological aspects.Eur Paediatr J. Neurol2002;6:15–23.
36.
SmalleySL: Autism and tuberous sclerosis.J Autism Dev Disord1998;28:407–414.
37.
AsanoE, ChuganiDC, MuzikO, : Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction.Neurology2001;57:1269–1277.
38.
FeinsteinC, ReissAL: Autism: The point of view from fragile X studies. J Autism Dev Disord1998;28:393–405.
39.
SkuseDH: Imprinting, the X-chromosome, and the male brain: Explaining sex differences in the liability to autism.PediatrRes2000;47:9–16.
40.
PeliosLV, LundSK: A selective overview of issues on classification, causation, and early intensive behavioral intervention for autism. Behav Modif2001;25:678–697.
41.
VolkmarF, CookEH, PomeroyJ, : Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues.J Am Acad Child Adolesc Psychiatry1999;38:(12 Suppl)32S–54S.
42.
AndresC: Molecular genetics and animal models in autistic disorder.Brain Res Bull2002;57:109–119.
43.
McDougleCJ, KreschLE, GoodmanWK, : A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder.Am Psychiatry J.1995;152:772–777.
44.
KlinA, JonesW, SchultzR, : Defining and quantifying the social phenotype in autism.Am Psychiatry J.2002;159:895–908.
Baron-CohenS: Do autistic children have obsessions and compulsions?Br J Clin Psychol1989;28:(Pt 3)193–200.
47.
DawsonJE, MatsonJL, CherryKE: An analysis of maladaptive behaviors in persons with autism, PDD-NOS, and mental retardation. Res Dev Disabil1998;19:439–448.
48.
McDougleCJ, ScahillL, McCrackenJT, : Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. ChildAdolescPsychia.tr Clin NAm2000;9:201–224.
49.
ChuganiDC, MuzikO, BehenM, : Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children.Ann Neurol1999;45:287–295.
50.
AndersonGM, CookEH: Pharmacogenetics. Promise and potential in child and adolescent psychiatry.Child Adolesc Psychiatr Clin NAm2000;9:23–42.
51.
CookEHJr, CourchesneR, LordC, : Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry1997;2:247–250.
PersicoAM, MiliterniR, BravaccioC, : Lack of association between serotonin transporter gene promoter variants and autistic disorder in two ethnically distinct samples.Am J Med Genet2000;96:123–127.
54.
LeschKP, MossnerR: Genetically driven variation in serotonin uptake: Is there a link to affective spectrum, neurodevelopmen-tal, and neurodegenerative disorders?Biol Psychiatry1998;44:179–192.
55.
PersicoAM, PascucciT, Puglisi-AllegraS, : Serotonin transporter gene promoter variants do not explain the hypersero-toninemia in autistic children.Mol Psychiatry2002;7:795–800.
56.
RitvoER, FreemanBJ, YuwilerA, : Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers.Psychopharmacol Bull1986;22:133–140.
57.
CampbellM, AdamsP, SmallAM, : Efficacy and safety of fenfluramine in autistic children.J Am Acad Child Adolesc Psychiatry1988;27:434–439.
58.
EkmanG, Miranda-LinneF, GillbergC, : Fenfluramine treatment of twenty children with autism.J Autism Dev Disord1989;19:511–532.
De LongGR, TeagueLA, McSwain KamranM: Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol1998;40:551–562.
62.
McDougleCJ, NaylorST, CohenDJ, : A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.Arch Gen Psychiatry1996;53:1001–1008.
63.
GordonCT, RapoportJL, HamburgerSD, : Differential response of seven subjects with autistic disorder to clomipramine and desipramine.Am Psychiatry J.1992;149:363–366.
64.
GordonCT, StateRC, NelsonJE, : A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.Arch Gen Psychiatry1993;50:441^47.
65.
OlssonI, SteffenburgS, GillbergC: Epilepsy in autism and autis-ticlike conditions. A population-based study.Arch Neurol1988;45:666–668.
66.
RemingtonG, SlomanL, KonstantareasM, : Clomipramine versus haloperidol in the treatment of autistic disorder A double-blind, placebo-controlled, crossover study.J Clin Psychopharmacol2001;21:440–444.
67.
De VaneCL, SalleeFR: Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience. J Clin Psychiatry1996;57:55–66.
68.
GoFS, MalleyEE, BirmaherB, RosenbergDR: Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder.J Child Adolesc Psychopharmacol1998;8:73–80.
69.
ChuganiDC, MuzikO, BehenM, : Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children.Ann Neurol1999;45:287–295.
70.
McBridePA, AndersonGM, HertzigME, : Effects of diagnosis, race, and puberty on platelet serotonin levels in autism and mental retardation.J Am Acad Child Adolesc Psychiatry1998;37:767–776.
71.
VitielloB: Pediatric psychopharmacology and the interaction between drugs and the developing brain.Can Psychiatry J.1998;43:582–584.
72.
GillbergC, SvennerholmL, Hamilton-HellbergC: Childhood psychosis and monoamine metabolites in spinal fluid. J Autism, Dev Disord1983;13:383–396.
73.
AndersonGM, HoshinoY: Neurochemical studies of autism, in Cohen DJ, Volkmar FR (eds): Handbook of Autism and Developmental Disorders, 2nd ed.New York, John Wiley & Sons, 1997, 325–343.
74.
AndersonLT, CampbellM, AdamsP, : The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children.J Autism Dev Disord1989;19:227–239.
75.
NieoullonA: Dopamine and the regulation of cognition and attention.Prog Neurobiol2002;67:53–83.
76.
SulzerD, JoyceMP, LinL, : Dopamine neurons make gluta-matergic synapses in vitro.J Neurosci1998;18:4588–4602.
77.
PurcellAE, JeonOH, ZimmermanAW, : Postmortem brain abnormalities of the glutamate neurotransmitter system in autism.Neurology2001;57:1618–1628.
78.
KingBH, WrightDM, HandenBL, : Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder.J Am Acad Child Adolesc Psychiatry2001;40:658–665.
79.
CohenIL, CampbellM, PosnerD, : Behavioral effects of haloperidol in young autistic children. An objective analysis using a within-subjects reversal design.J Am Acad Child Psychiatry1980;19:665–677.
80.
CampbellM, AndersonLT, MeierM, : A comparison of haloperidol and behavior therapy and their interaction in autistic children.J Am Acad Child Psychiatry1978;17:640–655.
81.
AndersonLT, CampbellM, GregaDM, : Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms.Am Psychiatry J.1984;141:1195–1202.
82.
AndersonLT, CampbellM, AdamsP, : The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children.J Autism Dev Disord1989;19:227–239.
83.
PerryR, CampbellM, AdamsP, : Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration.J Am Acad Child Adolesc Psychiatry1989;28:87–92.
84.
CampbellM, ArmenterosJL, MaloneRP, : Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study.J Am Acad Child Adolesc Psychiatry1997;36:835–843.
85.
NaruseH, NagahataM, NakaneY, : A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design.Acta Paedopsy-chiatr1982;48:173–184.
86.
FulopG, PhillipsRA, ShapiroAK, : ECG changes during haloperidol and pimozide treatment of Tourette's disorder.Am Psychiatry J.1987;144:673–675.
87.
GoodnickPJ, JerryJ, ParraF: Psychotropic drugs and the ECG: Focus on the QTc interval.Exp Opin Pharmacother2002;3:479–498.
88.
DestaZ, KerbuschT, FlockhartDA: Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).Clin Pharmacol Ther1999;65:10–20.
89.
DavisJM, JanicakPG: Efficacy and safety of the new antipsychotics.Lancet1994;343:476–477.
90.
PotenzaMN, HolmesJP, KanesSJ, McDougleCJ: Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study.J Clin Psychopharmacol1999;19:37–44.
91.
LeysenJE, GommerenW, EensA, : Biochemical profile of risperidone, a new antipsychotic.Pharmacol J. Exp Titer1988;247:661–670.
92.
ChouinardG, ArnottW: Clinical review of risperidone.Can Psychiatry J.1993;38:(Suppl 3)S89–S95.
93.
PurdonSE, LitW, LabelleA, JonesBD: Risperidone in the treatment of pervasive developmental disorder.Can Psychiatry J.1994;39:400–405.
94.
McDougleCJ, HolmesJP, CarlsonDC, : A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.Arch Gen Psychiatry1998;55:633–634.
95.
PerryR, PatakiC, Munoz-SilvaDM, : Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up.J Child Adolesc Psychopharmacol1997;7:167–179.
96.
McDougleCJ, HolmesJP, BronsonMR, : Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study.J Am Acad Child Adolesc Psychiatry1997;36:685–693.
97.
NicolsonR, AwadG, SlomanL: An open trial of risperidone in young autistic children.J Am Acad Child Adolesc Psychiatry1998;37:372–376.
98.
MeltzerHY, McGurkSR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophr Bull1999;25:233–235.
99.
KrebsS, DormannH, Muth-SelbachU, : Risperidone-induced cholestatic hepatitis.Eur Gastroenterol J. Hepatol2001;13:67–69.
100.
SzigethyE, WiznitzerM, BranickyLA, : Risperidone-induced hepatotoxicity in children and adolescents? A chart review study.J Child Adolesc Psychopharmacol1999;9:93–98.
101.
MandokiMW: Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side-effects?J Child Adolesc Psychopharmacol1995;5:49–67.
102.
ZuddasA, LeddaMG, FrattaA, : Clinical effects of clozapine on autistic disorder.Am Psychiatry J.1996;153:738.
103.
HorriganJP, BarnhillLJ, CourvoisieHE: Olanzapine in PDD.J Am Acad Child Adolesc Psychiatry1997;36:1166–1167.
104.
MartinA, KoenigK, ScahillL, BregmanJ: Open-label quetiapine in the treatment of children and adolescents with autistic disorder.J Child Adolesc Psychopharmacol1999;9:99–107.
105.
WeinbergWA, BrumbackRA: Primary disorder of vigilance: A novel explanation of inattentiveness, daydreaming, boredom, restlessness, and sleepiness.JPediatr1990;116:720–725.
106.
WeinbergWA, SchraufnagelCD, HarperCR, BrumbackRA: Algorithms for the treatment of affective illness, primary disorder of vigilance, and task-dependent attention disorders (learning disabilities) in children and adolescents.J Child Neurol1996;11:220–227.
107.
SmalleySL, McCrackenJ, TanguayP: Autism, affective disorders, and social phobia.Am J Med Genet1995;60:19–26.
LainhartJE, FolsteinSE: Affective disorders in people with autism: A review of published cases.J Autism Dev Disord1994;24:587–601.
110.
PivenJ, GayleJ, ChaseGA, : A family history study of neu-ropsychiatric disorders in the adult siblings of autistic individuals.J Am Acad Child Adolesc Psychiatry1990;29:177–183.
111.
CostelloEJ, PineDS, HammenC, : Development and natural history of mood disorders.Biol Psychiatry2002;52:529–542.
112.
WeckerlyJ: Pediatric bipolar mood disorder.J Dev Behav Pediatr2002;23:42–56.
113.
SchraufnagelCD, BrumbackRA, HarperCR, WeinbergWA: Affective illness in children and adolescents: Patterns of presentation in relation to pubertal maturation and family history.J Child Neurol2001;16:553–561.
114.
MarstonGM, PerryDW, RoyA: Manifestations of depression in people with intellectual disability.Intellect J. Disabil Res1997;41:476–480.
115.
DavisJP, JuddFK, HerrmanH: Depression in adults with intellectual disability. Part 2: A pilot study.Aust N Z Psychiatry J.1997;31:243–251.
116.
GellerB, LubyJ: Child and adolescent bipolar disorder: A review of the past 10 years.J Am Acad Child Adolesc Psychiatry1997;36:1168–1176.
117.
KomotoJ, UsuiS, HirataJ: Infantile autism and affective disorder.J Autism Dev Disord1984;14:81–84.
118.
GhaziuddinM, GhaziuddinN, GredenJ: Depression in persons with autism: Implications for research and clinical care.J Autism Dev Disord2002;32:299–306.
119.
VitriolC, FarberB: Stimulant medication in certain childhood disorders.Am Psychiatry J.1981;138:1517–1518.’.
120.
QuintanaH, BirmaherB, StedgeD, : Use of methylphenidate in the treatment of children with autistic disorder.J Autism Dev Disord1995;25:283–294.
121.
GellerB, GuttmacherLB, BleegM: Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity.Am Psychiatry J.1981;138:388–389.
122.
SchmidtK: The effect of stimulant medication in childhood-onset pervasive developmental disorder—A case report.J Dev Behav Pediatr1982;3:244–246.
123.
VolkmarFR, HoderEL, CohenDJ: Inappropriate uses of stimulant medications.Clin Pediatr (Phila)1985;24:127–130.
124.
AmanMG, LangworthyKS: Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders.J Autism Dev Disord2000;30:451–459.
125.
HandenBL, JohnsonCR, LubetskyM: Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.J Autism Dev Disord2000;30:245–255.
126.
SpencerT, WilensT, BiedermanJ: Psychotropic medication for children and adolescents.Child Adolesc Clin N Am1995;4:1, 97–121.
127.
CourchesneE, TownsendJ, AkshoomoffNA, : Impairment in shifting attention in autistic and cerebellar patients.Behav Neu-rosci1994;108:848–865.
128.
CourchesneE, PressGA, Yeung-CourchesneR: Parietal lobe abnormalities detected with MR in patients with infantile autism. AJR Am Roentgenol J.1993;160:387–393.
129.
BrumbackRA: Is depression a neurologic disease?Neurol Clin1993;11:79–104.
130.
BrumbackRA, WeinbergWA: Pediatric behavioral neurology: An update on the neurologic aspects of depression, hyperactivity, and learning disabilities.Neurol Clin1990;8:677–703.
131.
GhaziuddinM, Weidmer-MikhailE, GhaziuddinN: Comorbidity of Asperger syndrome: A preliminary report.Intellect J. Disabil Res1998;42:(Pt4)279–283.
132.
van der GeestJN, KemnerC, CamffermanG, : Eye movements, visual attention, and autism: A saccadic reaction time study using the gap and overlap paradigm. Biol Psychiatry2001;50:614–619.
133.
MinshewNJ, LunaB, SweeneyJA: Oculomotor evidence for neo-cortical systems but not cerebellar dysfunction in autism.Neurology1999;52:917–922.
134.
PierceK, CourchesneE: Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism.Biol Psychiatry2001;49:655–664.
135.
BuitelaarJK, van der GaagRJ, van der HoevenJ: Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: Results of an open-label study. J Clin Psychiatry1998;59:56–59.
136.
FankhauserMP, KarumanchiVC, GermanML, : A double-blind, placebo-controlled study of the efficacy of transdermal cloni-dine in autism.J Clin Psychiatry1992;53:77–82.
137.
JaselskisCA, CookEH, FletcherKE, LeventhalBL: Clonidine treatment of hyperactive and impulsive children with autistic disorder.J Clin Psychopharmacol1992;12:322–327.
138.
CampbellM, AndersonLT, SmallAM, : Naltrexone in autistic children: behavioral symptoms and attentional learning.J Am Acad Child Adolesc Psychiatry1993;32:(6)1283–1291.
139.
Willemsen-SwinkelsSH, BuitelaarJK, NijhofGJ, van EngelandH: Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies. Arch Gen Psychiatry1995;52:766–773.
140.
Willemsen-SwinkelsSH, BuitelaarJK, van EngelandH: The effects of chronic naltrexone treatment in young autistic children: A double-blind placebo-controlled crossover study. Biol Psychiatry1996;39:1023–1031.
141.
Di MartinoA, TuchmanRF: Antiepileptic drugs: Affective use in autism spectrum disorders. Pediatr Neurol2001;25:199–207.
142.
MuzinaDJ, El-SayeghS, CalabreseJR: Antiepileptic drugs in psychiatry—focus on randomized controlled trial.Epilepsy Res2002;50:195–202.
143.
TuchmanRF, RapinI: Regression in pervasive developmental disorders: Seizures and epileptiform electroencephalogram correlates.Pediatrics1997;99:560–566.
ShinnarS, RapinI, ArnoldS, : Language regression in childhood.Pediatr Neurol2001;24:183–189.
146.
NassR, DevinskyO: Autistic regression with rolandic spikes.Neuropsychiatry Neuropsychol Behav Neurol1999;12:193–197.
147.
PitkanenA: Drug-mediated neuroprotection and antiepileptoge-nesis: Animal data.Neurology2002;59:(9 Suppl 5)S27–S33.
148.
ColeAJ, DichterM: Neuroprotection and antiepileptogenesis: Overview, definitions, and context.Neurology2002;59:(9 Suppl 5)S1–S2.
149.
DaileyJW, ReithME, SteidleyKR, : Carbamazepine-induced release of serotonin from rat hippocampus in vitro.Epilepsia1998;39:1054–1063.
150.
BafMH, SubhashMN, LakshmanaKM, RaoBS: Alterations in monoamine levels in discrete regions of rat brain after chronic administration of carbamazepine.Neurochem Res1994;19:1139–1143.
151.
BafMH, SubhashMN, LakshmanaKM, RaoBS: Sodium valproate induced alterations in monoamine levels in different regions of the rat brain.Neurochem Int1994;24:67–72.
152.
CasanovaMF, BuxhoevedenDP, SwitalaAE, RoyE: Minicolum-nar pathology in autism.Neurology2002;58:428–432.
153.
CasanovaMF, BuxhoevedenDP, SwitalaAE, RoyE: Neuronal density and architecture (gray level index) in the brains of autistic patients.J Child Neurol2002;17:515–521.
154.
CarlssonML: Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate-serotonin interactions for pharmacotherapy.Neural J. Transm1998;105:525–535.
155.
BlueME, NaiduS, JohnstonMV: Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome.Exp Neurol1999;156:345–352.
156.
BelsitoKM, LawPA, KirkKS, : Lamotrigine therapy for autistic disorder A randomized, double-blind, placebo-controlled trial.J Autism Dev Disord2001;31:175–181.
157.
BaumanML, KemperTL: Neuroanatomic observations of the brain in autism, in BaumanML, KemperTL (eds): The Neurobiology of Autism.Baltimore and London, The Johns Hopkins University Press, 1994, 119–145
158.
PerryEK, LeeML, Martin-RuizCM, : Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain.Am Psychiatry J.2001;158:1058–1066.
159.
ChezMG, NowinskiCV, BuchananCP, JonesC: Donepezil (Ari-cept) use in children with autistic spectrum disorders.Am Neu-rol2000;48:541.
160.
HardanAY, HandenBL: A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder.J Child Adolesc Psychopharmacol2002;12:3, 237–241.
161.
MinshewN, GoldsteinG, SiegelD: Neuropsychological functioning in autism: Profile of a complex information processing disorder.J Int Neuropsychol Soc1997;3:303–316.
Van den BergheG, JaekenJ: Adenylosuccinase deficiency. Adv Exp Med Biol1986;195:(Pt A)27–33.
164.
SalernoC, CrifòC, CuratoloP, CiardoF: Effect of uridine administration to a patient with adenylosuccinate lyase deficiency.Adv Exp Med Biol2000;486:75–78.
165.
CarltonPL, ManowitzP: Dopamine and schizophrenia: An analysis of the theory.Neurosci Biobehav Rev1984;8:137–151.
166.
GustafssonL: Inadequate cortical feature maps: A neural circuit theory of autism.Biol Psychiatry1997;42:1138–1147.
167.
VitielloB: Psychopharmacology for young children: Clinical needs and research opportunities.Pediatrics2001;108:983–989.
168.
ArnoldLE, AmanMG, MartinA, : Assessment in multisite randomized clinical trials of patients with autistic disorder: The Autism RUPP Network. Research Units on Pediatric Psychopharmacology.J Autism Dev Disord2000;30:99–111.
